Using oncolytic viruses to exploit endogenous TCR signaling for modulation of CAR T phenotype and function against solid tumors 4322

Abstract Description We used C57BL/6 mice bearing B16-F10 tumors expressing EGFRviii, treated with anti-EGFRviii CAR T cells and the oncolytic virus vesicular stomatitis virus (VSV). TCR signaling in CAR T cells was investigated using the novel Tocky transgenic mouse model, which reports T cell activation over time using an unstable fluorescent protein reporter of Nr4a3. We further investigated CAR T phenotypes using CyTOF and scRNA-Seq. Using an MHC I tetramer for the dominant VSV epitope VSV-N52-59, we found that 20-50% of transfused CAR T adopted TCR specificity against VSV-N (TCR-primed), far above the predicted frequency in a naïve T cell repertoire. Ex vivo, these TCR-primed CAR T produced increased levels of Granzyme B and IFNγ over tetramer negative CAR T against either TCR or CAR targets. TCR-primed CAR had decreased levels of T cell activation as compared to non-TCR-primed CAR. CyTOF and scRNA-Seq analyses demonstrated a hyper-effector phenotype among TCR-primed CAR, with increased expression of T-bet, CD44, Granzyme B, IFNγ, and perforin. TCR sequencing revealed hyper-expansion of VSV N-specific CAR T cells and little overlap in clonotypes between CAR T co-treated with PBS versus VSV. Overall, CAR T cells that undergo endogenous anti-viral TCR priming and signaling appear to adopt a unique phenotype that promotes their cytotoxic function. These data suggest that engineering anti-viral TCRs into CAR T could be used to improve efficacy with OV boosting. Funding Sources Supported by NIH T32GM145408 and NIH R01CA269384. Topic Categories Vaccines and Immunotherapy (VAC)